Why the study?
Does adriamycin-induced cardiomyopathy alter the beta-adrenergic receptor-adenylate cyclase system in rabbits?
Does adriamycin-induced cardiomyopathy alter the beta-adrenergic receptor-adenylate cyclase system in rabbits?
Answers are grounded in this paper and cite their sources.
Adriamycin-induced chronic biventricular failure in rabbits is associated with abnormal beta-adrenergic transmembrane signaling, likely due to post-receptor abnormalities.
We investigated alterations in the beta-adrenergic receptor-adenylate cyclase system in rabbits with congestive heart failure induced by adriamycin cardiotoxicity. A dose of 24 mg/kg adriamycin was administered over 16 weeks in 16 rabbits. Five of them died and 4 of them could not tolerate the full dose of adriamycin. Complete data were obtained in the remaining 7 rabbits. Another 7 rabbits received physiological saline for the same period and served as controls. Plasma norepinephrine concentration increased in adriamycin-treated rabbits, but not in the control rabbits. Cardiac output was lower in the adriamycin-treated group than in the control group. Both the left and right ventricular end-diastolic pressure were higher in the adriamycin-treated group. The density of myocardial beta-adrenergic receptors and the norepinephrine content were reduced in both ventricles in the adriamycin-treated group. Basal and isoproterenol-, sodium fluoride- and forskolin-stimulated adenylate cyclase activities were lower in the adriamycin-treated group. Thus, alterations in beta-adrenergic signaling occurred in both ventricles in animals with chronic biventricular failure induced by adriamycin. These may be the result of post-receptor abnormalities, including abnormalities of guanine nucleotide-binding proteins or of the catalytic unit of adenylate cyclase.
No takes yet. Share an insight, caveat, or question.
Nagami et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: